Natasha Madsen

Ms. Natasha Madsen

Bioneer A/S
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
NMNatasha Madsen
Natasha Madsen
BNBoye Schnack Nielsen
Boye Schnack Nielsen
SNSon Ly Nhat
Son Ly Nhat
Søren SkovSøren Skov
Søren Skov
MGMonika Gad
Monika Gad
JLJesper Larsen
Jesper Larsen
Tumor-associated macrophages often correlate with tumor progression, and therapies targeting immune cells in tumors have emerged as promising treatments. To select effective therapies, we established an in vitro 3D multicellular spheroid model including cancer cells, fibroblasts, and monocytes. We analyzed monocyte infiltration and differentiation in spheroids generated from fibroblasts and either of the cancer cell lines MCF-7, HT-29, PANC-1, or MIA PaCa-2. Monocytes rapidly infiltrated spheroids and differentiated into mature macrophages with diverse phenotypes in a cancer cell line-dependent manner. MIA PaCa-2 spheroids polarized infiltrating monocytes to M2-like macrophages with high CD206 and CD14 expression, whereas monocytes polarized by MCF-7 spheroids displayed an M1-like phenotype. Monocytes in HT-29 and PANC-1 primarily obtained an M2-like phenotype but also showed upregulation of M1 markers. Analysis of the secretion of 43 soluble factors demonstrated that the cytokine profile between spheroid cultures differed considerably depending on the cancer cell line. Secretion of most of the cytokines increased upon the addition of monocytes resulting in a more inflammatory and pro-tumorigenic environment. These multicellular spheroids can be used to recapitulate the tumor microenvironment and the phenotype of tumor-associated macrophages in vitro and provide more realistic 3D cancer models allowing the in vitro screening of immunotherapeutic compounds.

23 June 2022 in Cellular Immunology
Verified
Journal Article
Open access
NMNatasha Madsen
Natasha Madsen
BNBoye Schnack Nielsen
Boye Schnack Nielsen
JLJesper Larsen
Jesper Larsen
MGMonika Gad
Monika Gad
In vitro cancer models that can identify novel immunomodulating compounds are essential. Using a 3D multi-cellular tumor spheroid (MCTS) model comprising cancer cells, fibroblasts, and macrophages, we tested tumor-associated macrophage (TAM)-inhibiting compounds (CCL2 Ab, CSF1R inhibitor, CSF1R Ab) and TAM-reprograming compounds (poly I:C, CD40 Ab, CD40 ligand) for their effects on monocyte infiltration and po-larization in tumor spheroids. For characterization of macrophage polarization, we measured the expression of CD206, CD163, CD86, MHC II, CD40, and CD14 and measured 43 soluble factors in the 3D MCTS cultures. 2D macrophage models were evaluated for comparison. A CSF1R inhibitor prevented infiltration of monocytes into pancreatic cancer spheroids, and macrophages treated with the inhibitor showed decreased expression of M2 markers. Treatment with a CD40 ligand and poly I:C induced M1 macrophage polarization in our models. We propose that these models can be used to improve the drug screening process of anti-cancer immunotherapies targeting macrophages.

14 May 2025 in Experimental Cell Research
Verified
Journal Article
Open access
NMNatasha Madsen
Natasha Madsen
BNBoye Schnack Nielsen
Boye Schnack Nielsen
ISIsabella Skandorff
Isabella Skandorff
CRCarlos Rodriguez-Pardo
Carlos Rodriguez-Pardo
SHSine Reker Hadrup
Sine Reker Hadrup
MGMonika Gad
Monika Gad
Advanced 3D heterospheroids, composed of cancer, fibroblast, and immune cells, serve as more physiologically relevant models for anticancer drug screening and immunotherapy research compared to traditional 2D cultures. This study aimed to optimize the culturing, dissociation, and analysis of heterospheroids, addressing limitations that restrict their broader use in immunotherapy research. Our study revealed significant effects of Human Plasma-Like culture medium on cell viability, necrotic core formation, and the spatial organization of cancer and fibroblast cells within heterospheroids compared to DMEM and RPMI media. In HT-29 heterospheroids, cell viability decreased from 75% in DMEM to 20% in HPLM, which was accompanied by increased necrotic core formation and elevated PD-L1 expression. TrypLE™ effectively dissociated heterospheroids but compromised immune cell viability and surface marker detection. In comparison, Accutase™ significantly reduced cell yield, while collagenase I preserved immune cell markers but affected those on cancer cells. Furthermore, we developed a luciferase-based assay to measure immune-mediated cancer cell killing in heterospheroids, excluding signals from non-target cells, such as dying fibroblasts and immune cells, without requiring spheroid lysis or dissociation. Our findings highlight the importance of tailoring experimental conditions to reflect specific tumor characteristics, thus enhancing the utility of heterospheroids in drug discovery and immunotherapy research.

29 October 2026 in Cancer Research Communications
Verified
Journal Article
Open access
ABAnne Louise. Blomberg
Anne Louise. Blomberg
WTWeihua Tian
Weihua Tian
JAJudit Pina. Agullet
Judit Pina. Agullet
NMNatasha Madsen
Natasha Madsen
KLKatrine Grove. Linde
Katrine Grove. Linde
SGSteffen Goletz
Steffen Goletz
Blockade of the PD-1/PD-L1 axis has transformed cancer immunotherapy, yet many patients fail to achieve durable responses. Although Fc glycoengineering by defucosylation is well established to enhance NK cell-mediated antibody-dependent cellular cytotoxicity through increased FcγRIIIa binding, its effects on other FcγRIIIa-expressing immune cells remain poorly understood. Using complementary human in vitro dendritic cell–lymphocyte coculture models, we compared non-glycosylated, wild-type, and defucosylated anti-PD-L1 antibody variants. Defucosylation enhanced FcγRIIIa binding and increased the relative frequency and activation of cytotoxic lymphocytes, particularly CD3⁺CD56⁺ NKT-like cells. Our findings identify a previously unrecognized mechanism whereby coordinated engagement of PD-L1 on dendritic cells and FcγRIIIa on lymphocytes alters cytotoxic lymphocyte composition. The changes in cytotoxic lymphocyte composition and activation induced by defucosylated anti-PD-L1 were associated with enhanced tumor killing in both human 2D and 3D cancer models, supporting Fc glycoengineering as a potential strategy to improve cancer immunotherapy.